- Home
- TALO vs ZLAB Comparison
TALO vs ZLAB Comparison
Compare TALO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | ZLAB |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TALO | ZLAB |
|---|---|---|
| Price | $11.20 | $17.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.30 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,554,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.06 | ★ 24.14 |
| 52 Week Low | $6.23 | $16.82 |
| 52 Week High | $12.20 | $44.34 |
Technical Indicators
Market Signals| Indicator | TALO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 29.56 |
| Support Level | $10.64 | $16.82 |
| Resistance Level | $11.23 | $18.29 |
| Average True Range (ATR) | 0.39 | 0.60 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 35.05 | 26.18 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.